Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status

Cancer Research

Volumn 60, Issue 1, 2000, Pages 129-133

  Esteller, Manel ^a   Tortola, Silvia ^c   Toyota, Minoru ^a   Capella, Gabriel ^b   Peinado, Miguel Angel ^c   Baylin, Stephen B ^a   Herman, James G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL DURAN I REYNALS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; REGULATOR PROTEIN;

ARTICLE; CANCER CELL CULTURE; COLORECTAL CARCINOMA; DNA METHYLATION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; HUMAN; HUMAN CELL; ONCOGENE K RAS; PRIORITY JOURNAL; PROMOTER REGION;

CARRIER PROTEINS; COLORECTAL NEOPLASMS; CPG ISLANDS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; GENE SILENCING; GENES, P53; GENES, RAS; HL-60 CELLS; HUMANS; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P14ARF;

EID: 0033985151     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Sherr, C. J. Cancer cell cycles. Science (Washington DC), 276: 1672-1677, 1996.
2. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
3. Chin, L., Pomerantz, J., and DePinho, R. A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem. Sci., 23: 291-296, 1998.
4. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky. D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
5. Kamb, A. Cell-cycle regulators and cancer. Trends Genet., 11: 136-140, 1995.
6. Hussussian, C. J., Struewing, J. P., Goldtein, A. M., Higgins, P. A. T., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial adenoma. Nat. Genet., 8: 15-21, 1994.
7. Quelle, D. E., Zindy, F., Ashmun, R. A., and Scherr, C. J. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 83: 993-1000, 1995.
8. ARF. Cell, 91: 649-659, 1997.
9. Sherr, C. J. Tumor surveillance via the ARF-p53 pathway. Genes Dev., 12: 2434-2442, 1998.
10. Pomerantz, J., Schreiber-Agus, N., Liegeois, N. J., Silverman, A., Alland, L., Chin, L., Poles, J., Chen, K., Orlow, I., Lee, H. W., Cordon-Cardo, C., and DePinho, R. A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell, 92: 713-723, 1998.
11. Zhang, Y., Xiong, Y., and Yarbrough, W. G. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell, 92: 725-734, 1998.
12. Kamijo, T., Weber, J. D., Zambetti, G., Zindy, F., Roussel, M. F., and Sherr, C. J. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. USA, 95: 8292-8297, 1998.
13. Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K., Hara, E., Vousden, K. H., and Peters, G. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J., 17: 5001-5014, 1998.
14. INK4a: a gene with dual capacity to encode unrelated proteins that inhibit cell cycle progression. Oncogene, 12: 2041-2044, 1996.
15. ARF encoding exons in T-cell acute lymphoblastic leukemia. Blood, 91: 1016-1020, 1998.
16. Robertson, K. D., and Jones, P. A. The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol. Cell. Biol., 18: 6457-6473, 1998.
17. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72: 141-196, 1998.
18. Herman, J. G., Umar, A., Polyak, K., Graff, J. R., Ahuja, N., Issa, J. P., Markowitz, S., Willson, J. K., Hamilton, S. R., Kinzler, K. W., Kane, M. F., Kolodner, R. D., Vogelstein, B., Kunkel, T. A., and Baylin, S. B. Incidence and functional consequences of hMLHI promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. USA, 95: 6870-6875, 1998.
19. Esteller, M., Corn, P. G., Urena, J. M., Gabrielson, E., Baylin, S. B., and Herman, J. G. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res., 58: 4515-4518, 1998.
20. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res., 59: 793-797, 1999.
21. INK4B. Cancer Res., 56: 722-727, 1996.
22. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., Rutter, J. L., Buckler, A., Gabrielson, E., Tockman, M., Cho, K. R., Hedrick, L., Bova, G. S., Isaacs, W., Koch, W., Schwab, D., and Sidransky, D. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
23. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
24. Capella, G., Cronauev-Mitra, S., Peinado, M. A., and Perucho, M. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors. Environ. Heath Persp., 93: 125-131, 1991.
25. Vermeulen, S. J., Chen, T. R., Speleman, F., Nollet, F., Van Roy, F. M., and Mareel, M. M. Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18 originate from one and the same patient? Cancer Genet. Cytogenet., 107: 76-79, 1998.
26. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
27. Markl, I. D., and Jones, P. A. Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer. Cancer Res., 58: 5348-5353, 1998.
28. ARF links the tumour suppressor p53 to Ras. Nature (Lond.), 395: 125-126, 1998.
29. Hainaut, P., Soussi, T., Shomer, B., Hollstein, M., Greenblatt, M., Hovig, E., Harris, C. C., and Montesano, R. Database of p53 gene somatic mutations in human tumors and cell lines: updated compilation and future prospects. Nucleic Acids Res., 25: 151-157, 1997.
30. Prives, C. Signaling to p53: breaking the MDM2-p53 circuit. Cell, 95: 5-8, 1998.
31. Rapp, L., and Chen, J. J. The papillomavirus E6 proteins. Biochim. Biophys. Acta, 1378: F1-F19, 1998.